Switch theme
Sign up to access all valuation multiples
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
1997
579
LTM Revenue $117M
Last FY EBITDA $17.8M
$631M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gyre Therapeutics has a last 12-month revenue (LTM) of $117M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Gyre Therapeutics achieved revenue of $106M and an EBITDA of $17.8M.
Gyre Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gyre Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $117M | XXX | $106M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $102M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 96% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $17.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $16.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $12.1M | XXX | $12.1M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Gyre Therapeutics's stock price is $7.
Gyre Therapeutics has current market cap of $659M, and EV of $631M.
See Gyre Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $631M | $659M | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Gyre Therapeutics has market cap of $659M and EV of $631M.
Gyre Therapeutics's trades at 6.0x EV/Revenue multiple, and 35.4x EV/EBITDA.
Equity research analysts estimate Gyre Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gyre Therapeutics has a P/E ratio of 54.5x.
See valuation multiples for Gyre Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $659M | XXX | $659M | XXX | XXX | XXX |
| EV (current) | $631M | XXX | $631M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 35.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 38.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 54.5x | XXX | 54.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -93.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGyre Therapeutics's last 12 month revenue growth is 7%
Gyre Therapeutics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Gyre Therapeutics's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gyre Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gyre Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gyre Therapeutics acquired XXX companies to date.
Last acquisition by Gyre Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Gyre Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gyre Therapeutics founded? | Gyre Therapeutics was founded in 1997. |
| Where is Gyre Therapeutics headquartered? | Gyre Therapeutics is headquartered in United States of America. |
| How many employees does Gyre Therapeutics have? | As of today, Gyre Therapeutics has 579 employees. |
| Who is the CEO of Gyre Therapeutics? | Gyre Therapeutics's CEO is Dr. Han Ying, PhD. |
| Is Gyre Therapeutics publicy listed? | Yes, Gyre Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Gyre Therapeutics? | Gyre Therapeutics trades under GYRE ticker. |
| When did Gyre Therapeutics go public? | Gyre Therapeutics went public in 2023. |
| Who are competitors of Gyre Therapeutics? | Similar companies to Gyre Therapeutics include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Gyre Therapeutics? | Gyre Therapeutics's current market cap is $659M |
| What is the current revenue of Gyre Therapeutics? | Gyre Therapeutics's last 12 months revenue is $117M. |
| What is the current revenue growth of Gyre Therapeutics? | Gyre Therapeutics revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Gyre Therapeutics? | Current revenue multiple of Gyre Therapeutics is 5.4x. |
| Is Gyre Therapeutics profitable? | Yes, Gyre Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
